The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu
Trial record 1 of 1 for:    NCT05995015
Previous Study | Return to List | Next Study

4SCAR19U T Cells Targeting B Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05995015
Recruitment Status : Recruiting
First Posted : August 16, 2023
Last Update Posted : October 12, 2023
Information provided by (Responsible Party):
Shenzhen Geno-Immune Medical Institute

Brief Summary:
The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.

Condition or disease Intervention/treatment Phase
B Cell Malignancies Biological: Universal CD19-specific CAR gene-engineered T cells Phase 1

Detailed Description:

Chimeric antigen receptor (CAR) T cell therapy has proven effective in treating B cell malignancies. However, the application itself is still limited by the high cost and long preparation time which often do not meet the urgent need of patients. In addition, some patients may suffer from long-term immunosuppression caused by tumor microenvironment or after radiotherapy and chemotherapy, resulting in exhaustion, aging and functional defects of the autologous T cells, which will eventually affect the quality of the CAR-T cells and affect the clinical efficacy.

The 4SCAR19U T cells are genetically engineered and manufactured in bulk amount that can be supplied off-the-shelf without being custom made from individual patients. The immediate availability of the CAR-T cells makes clinical treatment convenient and timely for rapid progressing disease or for the highly immune suppressed patients. This application can be time- and cost-effective. This novel approach may also overcome problems of functionally defective autologous T cells. The purpose of this clinical trial is to assess the feasibility, safety and efficacy of the 4SCAR19U T cell product in hematological malignancies. Another goal of the study is to learn more about the function of this novel product and its persistence in the patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Universal 4SCAR19U T Cell Therapy for the Treatment of Relapsed and Refractory B Cell Malignancies
Estimated Study Start Date : October 31, 2023
Estimated Primary Completion Date : September 30, 2026
Estimated Study Completion Date : December 31, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
Experimental: Universal 4SCAR19U cells to treat CD19-positive hematological malignancies Biological: Universal CD19-specific CAR gene-engineered T cells
Infusion of 4SCAR19U cells

Primary Outcome Measures :
  1. Safety of 4SCAR19U CAR-T cells infusion [ Time Frame: 24 weeks ]
    Safety of 4SCAR19U T cells in patients with relapsed and refractory B-ALL, BCL using CTCAE 4 standard to evaluate the level of adverse events

Secondary Outcome Measures :
  1. Anti-tumor activity of 4SCAR19U cells after infusion [ Time Frame: 1 year ]
    Objective responses (complete response (CR) + partial response (PR)) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age older than 6 months.
  2. Primary B cell surface expression of CD19.
  3. The KPS score over 80 points, and survival time is more than 1 month.
  4. Greater than Hgb 80 g/L.
  5. No contraindications to blood cell collection.

Exclusion Criteria:

  1. Accompanied with other active diseases, and difficult to assess response after treatment.
  2. Bacterial, fungal, or viral infection, unable to control.
  3. Living with HIV.
  4. Active HBV or HCV infection.
  5. Pregnant and nursing mothers.
  6. under systemic steroid treatment within a week of the treatment.
  7. Prior failed CAR-T treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05995015

Layout table for location contacts
Contact: Lung-Ji Chang, Ph.D +86-0755 8672-5195

Layout table for location information
China, Guangdong
Shenzhen Geno-Immune Medical Institute Recruiting
Shenzhen, Guangdong, China, 518000
Contact: Lung-Ji Chang, Ph.D    +86-0755 8672-5195   
Sponsors and Collaborators
Shenzhen Geno-Immune Medical Institute
Layout table for additonal information
Responsible Party: Shenzhen Geno-Immune Medical Institute Identifier: NCT05995015    
Other Study ID Numbers: GIMI-IRB-23001
First Posted: August 16, 2023    Key Record Dates
Last Update Posted: October 12, 2023
Last Verified: October 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shenzhen Geno-Immune Medical Institute:
Universal CAR-T
Additional relevant MeSH terms:
Layout table for MeSH terms